A Phase 2, Open-Label Study of Rucaparib in Patients With Platinum-Sensitive, Relapsed, High-Grade Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer (ARIEL2 Part1)

Trial ID # NCT01891344; ARIEL2 Part1
Phase II
Drug Class DNA Damage Repair Pathway Inhibitors: PARP
Drug Name Rucaparib
Alternate Drug Names Rubraca, CO-338, PF 01367338, AG-014699
Drugs in Trial Rucaparib
Eligible Participant

Platinum sensitive recurrence, ≥ 1 prior platinum-based therapy

Patients Enrolled


Therapy Setting


Study Design

Open-Label, Non-randomized


ORR, PFS, evaluated per RECIST


Exploratory: BRCA1/2; LOH (by FoundationFocus CDx BRCA LOH)


BRCA MUT (n=40) vs BRCA WT LOH high (n=82) vs BRCA WT LOH low (n=70):

ORR: 80 vs 29 vs 10%
PFS: 12.8 vs 5.7 vs 5.2 months, HR: 0.27 (0.16-0.44, p<0.0001); HR: 0.62 (0.42-0.90, p=0.011)

Clinically Significant Adverse Events

Serious AE: none
Grade 3-4 AE: anemia or decreased hemoglobin (22%), elevated liver enzymes (13%)


Improved ORR and PFS with rucaparib treatment in BRCA MUT patients; long term responders most often have homozygous deletion or rearrangements, which would not be susceptible to somatic reversion mutations


Swisher EM et al. Rucaparib in relapsed, platinum-sensitive high-grade ovarian carcinoma (ARIEL2 Part 1): an international, multicentre, open-label, phase 2 trial. Lancet Oncol (2017) 18(1):75-87

Swisher EM et al. Characterization of patients (pts) with long-term responses to rucaparib in recurrent ovarian cancer (OC). J Clin Oncol (2020) 38: (suppl; abstr 6015)

Swisher EM et al. Poster

Contact Us
Contact Us

We are here to help! Send us a message below or give us a call at (858) 657-0282.